Metformin Decreases Reactive Oxygen Species, Enhances Osteogenic Properties of Adipose-Derived Multipotent Mesenchymal Stem Cells In Vitro, and Increases Bone Density In Vivo

Due to its pleiotropic effects, the commonly used drug metformin has gained renewed interest among medical researchers. While metformin is mainly used for the treatment of diabetes, recent studies suggest that it may have further application in anticancer and antiaging therapies. In this study, we investigated the proliferative potential, accumulation of oxidative stress factors, and osteogenic and adipogenic differentiation potential of mouse adipose-derived stem cells (MuASCs) isolated from mice treated with metformin for 8 weeks. Moreover, we investigated the influence of metformin supplementation on mice bone density and bone element composition. The ASCs isolated from mice who were treated with metformin for 8 weeks showed highest proliferative potential, generated a robust net of cytoskeletal projections, had reduced expression of markers associated with cellular senescence, and decreased amount of reactive oxygen species in comparison to control group. Furthermore, we demonstrated that these cells possessed greatest osteogenic differentiation potential, while their adipogenic differentiation ability was reduced. We also demonstrated that metformin supplementation increases bone density in vivo. Our result stands as a valuable source of data regarding the in vivo influence of metformin on ASCs and bone density and supports a role for metformin in regenerative medicine.

[1]  K. Marycz,et al.  The effect of a sol–gel derived silica coating doped with vitamin E on oxidative stress and senescence of human adipose-derived mesenchymal stem cells (AMSCs) , 2016 .

[2]  K. Marycz,et al.  The Influence of Aging on the Regenerative Potential of Human Adipose Derived Mesenchymal Stem Cells , 2016, Stem cells international.

[3]  K. Marycz,et al.  Equine Metabolic Syndrome Affects Viability, Senescence, and Stress Factors of Equine Adipose-Derived Mesenchymal Stromal Stem Cells: New Insight into EqASCs Isolated from EMS Horses in the Context of Their Aging , 2015, Oxidative medicine and cellular longevity.

[4]  K. Marycz,et al.  The Effect of Age on Osteogenic and Adipogenic Differentiation Potential of Human Adipose Derived Stromal Stem Cells (hASCs) and the Impact of Stress Factors in the Course of the Differentiation Process , 2015, Oxidative medicine and cellular longevity.

[5]  K. Marycz,et al.  Effect of Metformin on Viability, Morphology, and Ultrastructure of Mouse Bone Marrow-Derived Multipotent Mesenchymal Stromal Cells and Balb/3T3 Embryonic Fibroblast Cell Line , 2015, BioMed research international.

[6]  K. Marycz,et al.  In Vitro and In Vivo Effects of Metformin on Osteopontin Expression in Mice Adipose-Derived Multipotent Stromal Cells and Adipose Tissue , 2015, Journal of diabetes research.

[7]  P. Baer.  Adipose-derived mesenchymal stromal/stem cells: An update on their phenotype in vivo and in vitro. , 2014, World journal of stem cells.

[8]  D. Harris,et al.  Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation , 2014, Journal of Translational Medicine.

[9]  K. Marycz,et al.  Therapeutic effect of adipose-derived mesenchymal stem cell injection in horses suffering from bone spavin. , 2013, Polish journal of veterinary sciences.

[10]  A. Goodship,et al.  The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing , 2013, Osteoporosis International.

[11]  John D Lambris,et al.  Does complement play a role in bone development and regeneration? , 2013, Immunobiology.

[12]  R. Andersson,et al.  Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells , 2013, BMC Cancer.

[13]  K. Struhl,et al.  Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth , 2012, Proceedings of the National Academy of Sciences.

[14]  Ming Yan,et al.  In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma , 2012, BMC Cancer.

[15]  H. Choi,et al.  Metformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cells. , 2012, Biochemical and biophysical research communications.

[16]  Jin-wei He,et al.  The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice , 2012, Journal of Bone and Mineral Metabolism.

[17]  J. Shieh,et al.  Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies , 2012, Gut.

[18]  S. Kalra,et al.  Metformin and the promise of geroprotection , 2012, Indian journal of endocrinology and metabolism.

[19]  B. Viollet,et al.  Cellular and molecular mechanisms of metformin: an overview. , 2012, Clinical science.

[20]  B. Viollet,et al.  Metformin Reduces Endogenous Reactive Oxygen Species and Associated DNA Damage , 2012, Cancer Prevention Research.

[21]  P. Ducluzeau,et al.  Insulin Resistance, Polycystic Ovary Syndrome and Metformin , 2012, Drugs.

[22]  T. Kourelis,et al.  Metformin and cancer: new applications for an old drug , 2012, Medical Oncology.

[23]  W. Tan,et al.  AICAR, a Small Chemical Molecule, Primes Osteogenic Differentiation of Adult Mesenchymal Stem Cells , 2011, The International journal of artificial organs.

[24]  A. Cortizo,et al.  Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats. , 2011, European journal of pharmacology.

[25]  A. Teti.  Bone Development: Overview of Bone Cells and Signaling , 2011, Current osteoporosis reports.

[26]  K. Marycz,et al.  Comparison of Behavior, Morphology and Morphometry of Equine and Canine Adipose Derived Mesenchymal Stem Cells in Culture , 2011 .

[27]  M. Ratajczak.  The emerging role of microvesicles in cellular therapies for organ/tissue regeneration. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[28]  Y. D. Kim,et al.  Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. , 2011, Bone.

[29]  Sandra J Shefelbine,et al.  BoneJ: Free and extensible bone image analysis in ImageJ. , 2010, Bone.

[30]  Ya-xiong Shi.  Diabetes and Cancer: A Consensus Report , 2010 .

[31]  Xulei Tang,et al.  Metformin reverses the deleterious effects of high glucose on osteoblast function. , 2010, Journal of diabetes and its complications.

[32]  B. Viollet,et al.  AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass. , 2010, Bone.

[33]  D. Harlan,et al.  Diabetes and Cancer , 2010, Diabetes Care.

[34]  Edward Giovannucci,et al.  Diabetes and Cancer , 2010, Diabetes Care.

[35]  Jing Hu,et al.  Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. , 2010, European journal of pharmacology.

[36]  X. Hou,et al.  Metformin reduces intracellular reactive oxygen species levels by upregulating expression of the antioxidant thioredoxin via the AMPK-FOXO3 pathway. , 2010, Biochemical and biophysical research communications.

[37]  Diana van Heemst,et al.  Insulin, IGF-1 and longevity. , 2010, Aging and disease.

[38]  N. Chiba,et al.  Osteoblast differentiation is functionally associated with decreased AMP kinase activity , 2009, Journal of cellular physiology.

[39]  Bolin Liu,et al.  Metformin induces unique biological and molecular responses in triple negative breast cancer cells , 2009, Cell cycle.

[40]  A. Thor,et al.  Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro , 2009, Cell cycle.

[41]  Xiang Cheng,et al.  Metformin inhibits nuclear factor κB activation and decreases serum high-sensitivity C-reactive protein level in experimental atherogenesis of rabbits , 2009, Heart and Vessels.

[42]  W. Tan,et al.  Influence of lactic acid on the proliferation, metabolism, and differentiation of rabbit mesenchymal stem cells , 2009, Cell Biology and Toxicology.

[43]  Jing Hu,et al.  Metformin regulates osteoblast and adipocyte differentiation of rat mesenchymal stem cells , 2008, The Journal of pharmacy and pharmacology.

[44]  S. Yano,et al.  Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. , 2008, Biochemical and biophysical research communications.

[45]  V. Anisimov,et al.  Metformin slows down aging and extends life span of female SHR mice , 2008, Cell cycle.

[46]  P. Mattila,et al.  Filopodia: molecular architecture and cellular functions , 2008, Nature Reviews Molecular Cell Biology.

[47]  D. Hardie.  Role of AMP‐activated protein kinase in the metabolic syndrome and in heart disease , 2008, FEBS letters.

[48]  Nahum Sonenberg,et al.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. , 2006, Cancer research.

[49]  M. Couturier,et al.  Metformin reduces angiotensin-mediated intracellular production of reactive oxygen species in endothelial cells through the inhibition of protein kinase C. , 2006, Biochemical pharmacology.

[50]  A. Cortizo,et al.  Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. , 2006, European journal of pharmacology.

[51]  B. Fanburg,et al.  Reactive oxygen species in cell signaling. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[52]  M. Owen,et al.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. , 2000, The Biochemical journal.

[53]  C. Catalano,et al.  The Effect of Intravenous Metformin on Glucose Metabolism During Hyperglycaemia in Type 2 Diabetes , 1992, Diabetic medicine : a journal of the British Diabetic Association.

[54]  L. Feldkamp,et al.  Practical cone-beam algorithm , 1984 .